Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02523092 · ClinicalTrials.gov registry record · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
A Phase 4 study of Sarcoidosis, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02523092: Recruiting Phase 4 study of Sarcoidosis, sponsored by University of California, San Francisco.
NCT02523092 is a Phase 4 study of Sarcoidosis that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 14 participants, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02523092, a Phase 4 study of Sarcoidosis, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Primary Outcome
Quantitative polymerase chain reaction assay was used to measure the gene expression for the gene CXCL9 using whole blood samples. The change in cycle threshold from before starting medication to the end of treatment was calculated. From this calculation, the number of participants that met the criteria of a 50% or greater drop in CXCL9 levels is reported.
Conditions Studied
Interventions
- DRUG Acthar gel
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What NCT02523092 shows while recruiting
NCT02523092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Acthar gel is the first listed.
NCT02523092 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02523092 about?
NCT02523092 is a clinical study titled "Use of CXCL9 as a Biomarker of Acthar Efficacy". The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
What is the current status of trial NCT02523092?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2022-11-03. Estimated completion is 2026-12.
What conditions does trial NCT02523092 study?
This clinical trial studies the following conditions: Sarcoidosis.
What interventions are being tested in trial NCT02523092?
The interventions under investigation include: Acthar gel (DRUG).
Who is sponsoring clinical trial NCT02523092?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02523092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02523092's enrollment target sits among peer trials
14 21st of 21 higher than 1 of 21 other Sarcoidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vitamin D Homeostasis in Sarcoidosis
RECRUITING · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
RECRUITING
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Cardiac Sarcoidosis Randomized Trial
RECRUITING · Phase 3
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
- NCT05183048 · 14 participants · Early Phase 1
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy